Answers are grounded in this paper and cite their sources.
Mycobacterium tuberculosis (MTB) and nontuberculous mycobacteria (NTM) are important worldwide health problems because they may challenge human immunity and cause chronic infections. This study presents a comparative overview of immune evasion mechanisms in multidrug-resistant MTB (MDR-MTB) and NTM, focusing on mechanisms supported by direct experimental evidence and those inferred from drug-susceptible MTB. Supported findings in MDR-MTB include LAM-mediated block of phagolysosomal fusion, depletion of PI3P by SapM, and Zmp1-mediated suppression of AIM2 inflammasome activation. Mutations in katG and rpoB confer resistance to isoniazid and rifampicin. However, these primarily affect drug susceptibility rather than immune modulation. Other processes, such as ESX-1–mediated membrane disruption, PPE protein interference with oxidative stress, and ubiquitination pathway evasion, are well described in drug-susceptible MTB and are inferred to contribute to MDR-MTB persistence. For NTM, experimental evidence demonstrates immune evasion through biofilm formation (glycopeptidolipids, PKS1, polyphosphate accumulation), active efflux pumps, and cytokine modulation via LAM and Toll-like receptor 2 (TLR2) blockade. NTM also inhibits phagolysosomal fusion using SapM and PtpA, while granuloma formation sustains long-term infection. Both bacteria use overlapping mechanisms, including inhibition of phagosome-lysosome fusion, modulation of cytokine responses, and granuloma formation, but differ in their ecological niches, transmission, and clinical presentations. These immune-evasive features complicate therapy, prolong treatment, and hamper vaccine development. Emerging therapeutics include autophagy inducers (e.g., rapamycin) and host-directed therapies (e.g., interferon-gamma). Future prospects include personalized medicine, innovative vaccination platforms such as messenger RNA-based techniques, and a One Health approach to address the interconnected issues of MDR-MTB and NTM. Thus, this review explicitly distinguishes experimentally validated immune evasion mechanisms underlying MDR-MTB from those extrapolated from drug-susceptible strains, while integrating evidence-based findings for NTM.
No takes yet. Share an insight, caveat, or question.
Nahar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: